PSC-833, a frontier in modulation of P-glycoprotein mediated multidrug resistance
Tóm tắt
The expression of drug efflux mechanisms by cancer cells during chemotherapy leads to multidrug resistance (MDR) and constitutes a major obstacle in the effective treatment of cancer. The most widely characterized drug efflex pump is P-glycoprotein (P-gp) and efforts are being directed towards identifying agents that reverse P-gp mediated drug resistance. PSC-833 is a non-immunosuppressive cyclosporin derivative that potently and specifically inhibits P-gp. The current review focuses on the elucidation of the mechanism of action of PSC-833 as a potential MDR reversing agent, using syngeneic multidrug resistant sublines of MDA435 human breast adenocarcinoma cell line that express increasing levels of P-gp. In vitro experiments indicate that PSC-833 interacts directly with P-gp with high affinity and probably interferes with the ATPase activity of P-gp. Studies in multidrug resistant tumor models confirm P-gp as the in vivo target of PSC-833 and demonstrate the ability of PSC-833 to reverse MDR leukemias and solid tumors in mice. Presently, PSC-833 is being evaluated in the clinic.
Tài liệu tham khảo
Gottesman MM, Hrycyna CA, Schoenlein PV, Germann UA, Pastan I: Genetic analysis of the multidrug transporter. Ann Rev Gen 29: 607-649, 1995
Cobb PW, Rothenberg ML: PSC: A multidrug resistance modulating agent. DN&P 8: 475-479, 1995
Ford J, Hait W: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42: 156-199, 1993
Twentyman PR: Modification of cytotoxic drug resistance by non-immunosuppressive cyclosporins. Br J Cancer 57: 254-258, 1988
Boesch D, Muller K, Poutier-Manzanendo A, Loor F: Restoration of daunomyein retention in multidrug resistant P388 cells by submicromolar concentrations of SDZ PSC 833. Exp Cell Res 196: 26-32, 1991
Twentyman PR, Bleehen NM: Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin. Eur J Cancer 27: 1639-1642, 1991
Archinal Mattheis A, Rzepka RW, Watanabe T, Kokubu N, Itoh Y, Combates NJ, Bair KW, Cohen D: Analysis of the interactions of SDZ PSC-833 ([3'keto-BMT1]-Val2]-cyclosporine), a multidrug resistance modulator, with P-glycoprotein. Oncol Res 7: 603-610, 1995
Erlisch PH, Moustafa ZA, Archinal-Mattheis AE, Newman MJ, Bair KW, Cohen D: The reversal of multidrug resistance in multicellular tumor spheroids by SDZ PSC-833. Anticancer Res 17: 129-134, 1997
Pinica-worms D, Rao VV, Kronauge JF, Croop JM: Characterization of multidrug resistance P glycoprotein transport function with an organotechnetium cation. Biochemistry 34: 12210-12220, 1993
Pinica-worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM: Functional imaging of multidrug resistant P-glycoprotein with an organotechnetium complex. Cancer Res 53: 977-984, 1995
Barbaries E, Kronauge J, Cohen D, Davison A, Jones AG, Croop JM: Characterization of P-glycoprotein transport and inhibition in vivo. Cancer Res 58: 276-282, 1998
Watanabe T, Naito M, Oh-hara T, Itoh Y, Cohen D, Tsuruo T: Modulation of multidrug resistance by SDZ PSC-833 in leukemic and solid-tumor-bearing mouse models. Jpn J Cancer Res 87: 184-193, 1996
Keller RP, Altermatt HJ, Donatcsh P, Zihlman H, Lasue JA, Hiestand PC: Pharmacologic interactions between the resistance modifying cyclosporine SDZPSC-833 and ctoposide (VP16-213) enhance in vivo cytotoxic activity and toxieity. Int J Cancer 51: 433-438, 1992
Rohlf DP, et al.: Circumvention of the multidrug resistance gene product to enhance the chemoresponsiveness of renal cell carcinoma in a xenograft model. J Urology (Baltimore) 151(Suppl 1): 338A, 1994
Watanabe T, Kokubo N, Roninson IB, Cohen D: Effect of Gly185 to Val substitution in human P-glycoprotein on the reversal activity of PSC-833. Proc Am Assoc Cancer Res 37: abstract # 227, 1996
Chen G, Duran GE, Lacayo NJ, Jaffrezou NJ, Dumonet C, Sikic BI: Multidrug resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype and resistance to cyclosporins. J Biol Chem 272: 5974-5982, 1997
Watanabe T, Kokubo N, Charnick SB, Naito M, Tsuruo T, Cohen D: Interaction of cyclosporin derivatives with the ATPase activity of human P-glycoprotein. British J Pharmacol 122: 241-248, 1997
Boote DJ, Dennis IF, Twentyman PR, Osborne RJ, Laburte C, Hensel S, Smyth JF, Brampton MH, Blechen NM: Phase I study of etoposide with SDZ PSC-833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 14: 610-618, 1996
Dalton WS: Drug resistance modulation in the laboratory and the clinic Semin. Oncol 20: 64-69, 1993
Fisher GA, Sikie BI: Clinical studies with modulators of multidrug resistance. Hematol and Oncol Cin North Am 9: 363-382, 1995
Erlichman C, Moore M, Thiessen J, DeAngelis C, Goodman P, Manzo J: A phase I trial of doxorubiein (D) and PSC833, a modulator of multidrug resistance (MDR). Proc ASCO 13: 134 abstract 330. 1994
Giacconne G, Linn SC, Catimel G, et al.: Phase I and pharmacokinetic study of SDZ PSC-833 per os in combination with doxorubicin in patients with solid tumors. Proc ASCO 14: 142 abstract 364, 1995
Collins HL, Fisher GA, Hausdorf J, Lum BL, Pearce T, Halsey J, Sikic B: Phase I trial of praclitaxel in combination with SDZ PSC 833, a multidrug resistance modulator. Proc ASCO 325 14: 181 abstract 406, 1995
Hausdorff J, Fisher GA, Hasley J, Collins HL, Lum BL, Brophy NA, Duran GE, Nix D, Pearce T, Sikic BI: A phase I trial of etoposide with the oral cyclosporin SDZ PSC 833, a modulator of multidrug resistance (MDR). Proc ASCO 14: 181 abstract 407, 1995
Sonneveld P, Lowenberg B, Vossebeld P, Malkhendi J, Covelli A, Deckker AW, Ossenkopela G, Muligan D, Verhoef G, Ferret A, Lin J, Gratwohl A, Kovesovics T, Burnett A: Dose-finding study of PSC-833, a novel MDR reversing agent with daunorubicin and ARA-C in untreated elderly patients with acute myeloid lcukemia (AML). Blood 90:(Suppl 1): abstract # 2517, 1997
Visani G, Milligan D, Leoni F, Chang J, Kelsy S, Marcus R, Powles R, Schey S, Covelli A: A phase I dose-finding study of PSC 833, a novel MDR reversing agent, with mitoxantronc, ctoposide and cytarabine (PSC-MEC) in poor prognosis acute leukemia (AML). Blood 90:(Suppl 1): abstract 2518, 1997
Advani R, Saba HI, Tallman M, Rowe JM, Wiernik PH, Ramej J, Dugan B, Lum B, Villena J, Sikic BI, Davis E, Paitta E, Litchman M, Greenberg P: Treatment of poor prognosis AML with PSC-833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC). Blood 90(Suppl 1): abstract # 2260, 1997
Fields H, Hochster C, Runowiz C, Speyer J, Goldberg C, Cohen C, Dottino P, Wadler S, Back G, Gretz H, Mandeli J, Holland J, Letvak L: SDZ-PSC-833/paclitaxel in paclitaxel refractory ovarian carcinoma: A phase II trial with renewed responses. Proc ASCO abstract # 1254, 1997